EUTOS Objectives  · 

The European LeukemiaNet (ELN) and Novartis have established the European Treatment and Outcome Study (EUTOS) for CML, an initiative designed to help European healthcare professionals to optimize treatment and achieve the best possible outcomes for patients with chronic lyeloid leukemia (CML)

Summary

The overall objectives are the formation of a CML alliance between academia and industry for the collection of baseline-, treatment- and outcome data of representative samples of CML patients of major European countries. This is achieved by expanding the current European
CML Registry and its sub registries to assess faster epidemiological data on CML, the current state of treatment, the implementation of the ELN recommendations for CML management, new prognostic models and prognosis adjusted treatments. The objectives are promoted by
quality controlled molecular monitoring using standardized RQ-PCR technologies and an international definition of molecular results, by drug monitoring including pharmacokinetics and monitoring patients’ compliance and by spread of excellence activities.
The project will make use of the ELN infrastructure and of existing leukemia study groups in the field of CML for accomplishment of the objectives and for dissemination and exploitation of project results.
The project will foster ELN-activities, promote implementation of ELN management recommendations, improve understanding and treatment of CML, and enhance outcome of CML across Europe and globally.
The project will have considerable medical and societal impact and can start immediately.

The overall objectives of this CML-Alliance are, to:

• collect baseline-, treatment- and outcome data of representative samples of CML patients of major European countries
• evaluate the implementation of the ELN recommendations for CML management (Blood 2006;108:1809-20.) as reference
• promote quality controlled molecular monitoring using standardized RQ-PCR technologies and establishment of an international definition of major molecular response
• assess the impact of therapeutic drug monitoring, pharmacokinetics and patients compliance on the course of CML
• foster continued medical education and spread of excellence • develop and validate a comprehensive prognostic model which allows to optimize individual treatment choices
• provide a platform for the expedited evaluation of new treatments

Created by: A. Hellenbrecht , generated 2007/12/20 , last changed: 2008/07/31